Company details
Inceptive
Builds AI foundation models to design RNA-based medicines with pharmaceutical partners.
Stability signals
- CEO
- Jakob Uszkoreit
- Founders
- Jakob Uszkoreit, Rhiju Das
- Total raised
- $120M disclosed seed and Series A rounds
- Founders' prior
companies - Unknown
- Recent evidence
Commercial Collaboration · Alnylam and Inceptive announced a strategic AI collaboration with $30 million upfront consideration and additional conditional milestone payments.
Scope: Inceptive Nucleics, Inc. global company with Berlin operations. No allocation to the Berlin office is established.
Evidence reviewed 2026-10-24. This claim does not establish overall financial stability.
Verification needed
At a glance
Open roles
5
activeNew this month
0
New openings
5
opened in the last 90 daysGerman requirement
0%
based on 5 of 5 rolesOpen roles over time
Open roles · 12 months
5open
2025-12 → 2026-11Month-end counts · Nov shows current open roles
5 open roles
- Berlin, Germany or Palo Alto, CA or Zurich
- 3
- Palo Alto, Berlin, or Zurich
- 1
- Berlin
- 1
Open roles · 5
- Data selection and quality evaluation for biological foundation modelsBerlin Onsite · Posted 30+ days agoNo German required
- Computational design of biological experiments for model developmentBerlin Onsite · Posted 30+ days agoNo German required
- Secure data infrastructure for AIBerlin Onsite · Posted 30+ days agoNo German required
- Foundation and generative models for biomoleculesBerlin Onsite · Posted 30+ days agoNo German required
- Open applyBerlin Onsite · Posted 30+ days agoNo German required